U056 Update on Cutaneous Reactions to Targeted and Immune Cancer Therapy
DESCRIPTION
Update on the latest cancer therapies and dermatologists' role in managing cutaneous toxicities. This session focuses on challenging diagnostic scenarios and management algorithms and guidelines. This activity has been approved by the American Board of Dermatology (ABD) for up to 10 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Review trends in cancer therapy and the resulting cutaneous toxicities.
Discuss challenging diagnostic scenarios.
Discuss challenging management scenarios and management algorithms.
SCHEDULE
7:00 AM
Diagnosis and management of cutaneous toxicities to targeted cancer therapies
Anisha Patel, MD, FAAD
7:25 AM
Diagnosis and management of cutaneous toxicities to immune cancer therapies
Meghan M. Heberton, MD, FAAD
7:50 AM
Q&A
DIRECTOR
Anisha Patel, MD, FAAD
SPEAKER
Meghan M. Heberton, MD, FAAD
HANDOUTS
DISCLOSURES
Meghan M. Heberton, MD, FAAD
Blueprint Medicines – Advisory Board(Fees);
Anisha Patel, MD, FAAD
AnaptysBio – Investigator(Grants/Research Funding); Asymmetric Therapeutics, LLC – Consultant (1099 relationship)(Fees); Deciphera Pharmaceuticals, Inc. – Consultant(Fees); Erasca – Consultant (1099 relationship)(Fees); Hoth Therapeutics – Investigator(Grants/Research Funding); Janssen Scientific Affairs, LLC – Consultant (1099 relationship)(Fees); Lutris – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Advisory Board(Fees), Other(No Compensation Received); OnQuality Pharmaceuticals, Ltd. – Consultant(Fees), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Repare therapeutics – Consultant (1099 relationship)(Fees); SynOx Therapeutics – Consultant (1099 relationship)(Fees);